Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company has two clinical-stage programs and a second program that is discovery-stage and partnered with another company. Lux... Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company has two clinical-stage programs and a second program that is discovery-stage and partnered with another company. Luxeptinib, its panFMS-like tyrosine kinase 3 / pan-Bruton's tyrosine kinase inhibitor, is enrolling patients in a Phase 1, multicenter, open label, dose-escalation study with expansions to assess the safety, tolerability, PK, and preliminary efficacy of CG-806 in patients with chronic lymphocytic leukemia (CLL/SLL) or non-Hodgkin lymphomas (NHL). HM43239 is an oral potent myeloid kinome inhibitor, targeting a constellation of kinases operative in myeloid malignancies. Show more
SAN DIEGO and TORONTO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (βAptoseβ or the βCompanyβ) (NASDAQ: APTO, TSX: APS),Β a clinical-stage precision oncology company developing...
Peer-reviewed publication details unique TUS mechanism of action TUS+VEN combination synthetic lethality overcomes resistance to VEN Tuspetinib prolongs survival in multiple AML models resistant...
TUS+VEN+AZA Triplet Frontline Therapy in Newly Diagnosed AML Patients Now Enrolling at U.S. SitesTUS and TUS+VEN Broadly Active Across AML Populations, with Favorable SafetyTUS-based therapies are...
Tuspetinib selected for a prestigious national clinical research program for ability to target broad spectrum of AML and MDS populations Trials to test tuspetinib in targeted drug combinations for...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.053 | 26.9035532995 | 0.197 | 0.3895 | 0.17 | 72002092 | 0.26427624 | CS |
4 | 0.065 | 35.1351351351 | 0.185 | 0.3895 | 0.17 | 19532194 | 0.26201693 | CS |
12 | -0.155 | -38.2716049383 | 0.405 | 0.4162 | 0.13 | 6688656 | 0.25831231 | CS |
26 | -0.55 | -68.75 | 0.8 | 0.81 | 0.13 | 3402571 | 0.27100232 | CS |
52 | -2.11 | -89.406779661 | 2.36 | 2.68 | 0.13 | 1774997 | 0.30144547 | CS |
156 | -21.35 | -98.8425925926 | 21.6 | 23.25 | 0.13 | 752898 | 2.99293556 | CS |
260 | -82.25 | -99.696969697 | 82.5 | 138.7875 | 0.13 | 1054259 | 44.52615069 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.